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ABSTRACT
An existence of transdermal delivery tool, proniosomal gel, has established to showed remarkable development for lipophilic/hydrophilic drugs over 
additional formulations. Newer drugs of lipophilic nature emerge poor bioavailability, irregular absorption, and pharmacokinetic changes. Therefore, 
this novel drug delivery system has been proved advantageous over other oral and topical delivery of drug candidates to bypass such disruption. This 
proniosomal gel basically is a compact semi-solid liquid crystalline (gel) composed of non-ionic surfactants easily formed on dissolving the surfactant 
in a minimal amount of acceptable solvent and the least amount of aqueous phase and phosphate buffer. Topical application of gel under occlusive 
condition during which they are converted into nisomes due to hydration by water in the skin present itself. Proniosomal gels are typically present in 
transparent, translucent, or white semisolid gel texture, which makes them physically stable throughout storage and transport. This review provides 
an important overview of the preparation, formulation, evaluation, and application of proniosome gel as a drug delivery carrier.
Keywords: Vesicular drug delivery, Proniosomal gel, Non-ionic surfactants, Coacervation phase separation, Topical drug delivery.
INTRODUCTION
At the time of the ancient day’s humans used cool water, a leaf, dirt, or mud 
was their first soothing application purpose. Understands the inherent 
tendency of nature, birds, and animals continued to struggles genesis 
of mesapatonia, practicing the treatment by the pharmacist and share 
his knowledge for the benefit of suffered people. Tablets were used for 
illness, different routes of administration available for successive delivery 
of designed dosage forms [1]. Development of a formulation depends on 
the characterization of the active ingredient. Oral administration is a most 
preferred route with high patient compliance. However, bioavailability 
is poor progress observed reasons behind were poor solubility of drug 
candidate followed by less absorption [2]. Less aqueous solubility is 
the major drawback encountered with the formulation design of new 
chemical moiety [3]. Recent research focused on the development of 
hydrophobic active pharmaceutical ingredients [4] and reported that 
around 40% of new drugs showed poor aqueous solubility [5]. Different 
techniques have been used to improve solubility and better dissolution 
rates of poorly water-soluble drugs which include as particle size 
reduction, nano ionization, cosolvency, hydrotropy, pH adjustment, sono 
crystallization, supercritical fluid process, solid dispersion, inclusion 
complexation, self-emulsifying or self-micro emulsifying systems, and 
liquisolid methods [6]. A number of novel drug delivery systems have 
emerged in various routes of administration, to achieve controlled and 
targeted drug delivery. Encapsulation of the drug in vesicular structures 
is one such system, and a number of vesicular drug delivery systems 
such as liposomes, niosomes, transfersomes, and pharmacosomes 
were developed [7]. Oral solid dosage forms face problems such as 
gastric drug/enzyme instability and first-pass metabolism. Oral route 
has any further problems such as an unpleasant taste, odor, and color. 
Transdermal dosage forms, an alternative to conventional dosage 
formulations, are becoming popular due to their exclusive advantages. 
Improved bioavailability, controlled absorption, extra uniform plasma 
levels, painless and reduced side effects easy application [8]. However, 
benefits from the transdermal route, disadvantages of their formulations 
such as ointments, creams, and lotions with many disadvantages with 
sticky in nature, poor spreadability, and concerned about its stability 
issue.
Topical administration is the most preferred route for local delivery 
of therapeutic agents due to its convenience and easy access. The 
specific challenge of designing a therapeutic system is to achieve 
an optimal concentration of a certain drug at its site of action for an 
appropriate time span [9]. Vesicular drug delivery systems are novel 
means to increase the bioavailability of the enclosed drug with more 
advantages over than the conventional dosage forms. Liposomes were 
first in such type of delivery systems, but it was not so successful due 
to their several drawbacks [10]. Niosomes or non-ionic surfactant 
vesicles are a microscopic lamellar structure of size range 10–1000 nm 
consisting of spherical, uni- or multi-lamellar and polyhedral vesicles 
in aqueous media [11]. Butnoisomes exhibits physicochemical stability 
problem on storage of dispersion, for example, aggregation, fusion, 
drug leakage or hydrolysis of the active compounds, thus raising 
concerns over their adoption [12]. Proniosomes were prepared as a 
dry powder for reconstitution before use by preserving the physical 
and chemical integrity of vesicles [13]. For transdermal delivery 
proniosomes were prepared as gel-like concentrated niosomes suitable 
for topical application [14]. Proniosomes are semisolid, liquid crystal 
(gel) product of nonionic surfactant which on hydration converts into 
niosomes [15,16]. Proniosomes when applied onto the skin surface 
transform into niosomes due to the hydration by water from the skin 
which would provide an occlusive condition and offer a potential for 
drug delivery through the transdermal route. The gel property of 
proniosomes maintaining better skin penetration and physicochemical 
properties. Both phospholipids and non-ionic surfactants in 
proniosomes can act as penetration enhancers since it was found that 
some phospholipids are able to fluidize the stratum corneum lipid 
bilayers and disperse through them [17]. Proniosomal gels are typically 
present in transparent, translucent, or white semisolid gel texture, which 
makes them physically stable throughout storage and transport. The 
present article is elaborate an extensive review covering components 
used for proniosomal gel formulation combined with its formulation 
overview and biopharmaceutical parameters of the published research 
works on a proniosomal gel with distinct pharmaceutical products.
FORMULATION INGREDIENTS CONCERN
In spite of phospholipids and non-ionic surfactants in proniosomes 
can act as Penetration enhancers, since it was found that some 
phospholipids are able to fluidize the stratum corneum lipid bilayers 
and diffuse through them [17], whereas cholesterol gives stability and 
permeability to the vesicles.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Surfactants
It is acting as solubilizers, wetting agents, emulsifiers, and permeability 
enhancers [18]. Chiefly non-ionic surfactants were used in the 
formulation of proniosomal gel. Based on the hydrophile-lipophile 
balance (HLB) values of the available surfactants, mainly categorized 
into w/o emulsifying agent (HLB 3–8) and o/w emulsifying agent 
(HLB 8–16) [19] usually the HLB value of 4–8 will give the vesicles 
with high compatibility. List of common nonionic amphiphiles used in 
proniosome formulations were mentioned in Table 1 [20].
Lecithin
Mainly acts as membrane stabilizers mostly used two varieties, 
i.e.,  Soya lecithin and egg lecithin former one collected from the soya 







It is an important component used in the design of proniosomes which 
gives stability and penetrability to the vesicles. Entrapment efficiency 
(EE) depends on the concentration of cholesterol used. Cholesterol may 
reinforce bilayer assembly; vesicles cannot be built without the addition 
of cholesterol, with higher concentrations of cholesterol decreasing the 
time required for niosome assembly. It prevents accumulation by the 
inclusion of molecules that stabilize the system against the formation of 
an aggregate by repulsive steric or electrostatic effects [23].
Solvent and aqueous phase
Alcohol has shown a great effect on vesicle size and drug permeation 
rate of a proniosomal formulation. Different size of vesicles formed 
using different alcohols as they follow the order:Ethanol>propanol> 
butanol>isopropanol. Phosphate buffer 7.4, 0.1% glycerol, hot water is 
used as the aqueous phase in preparation of proniosomes [24].
Carrier material
The use of maltodextrin based proniosomes preparation permitted 
flexibility in the ratio of surfactant and other components which can be 
incorporated [25]. In addition to this; it increases the surface area and 
hence efficient loading. The carriers should be safe and non-toxic, free-
flowing, poor solubility in the loaded mixture solution and good water 
solubility for ease of hydration. Commonly used carriers are listed, 
they are sorbitol, mannitol, glucose, lactose, and sucrose stearate [15]; 
habitually used carriers are listed below [26].
a. Maltodextrin.
b. Sorbitol.





The drug selection criteria could be based on the following assumptions.
1. The low aqueous solubility of drugs.
2. High dosage frequency of drugs.
3. Short half-life.
4. Controlled drug delivery suitable drugs.
5. Drugs are having more adverse effects [27].
Advantages
•	 Proniosomes	were	 easily	prepared	 and	did	not	 require	 special	






In general, proniosomes were divided into the following types [29].
1. Semi-solid liquid crystal gel.
2. Dry granular powder Fig. 1.
Methods of preparation of proniosomal gel
a. Coacervation phase separation.
b. Slow spray coating method.
c. Slurry method.
Coacervation phase separation
Proniosomal formulae were prepared by a method reported by Alsarra 
et al. [30] with slight modification, using different types of non-
ionic surfactants, lecithin, and cholesterol. Appropriate amounts of 
proniosomal components mixed together with the drug were mixed with 
2.5 ml of absolute ethanol in a clean and dry, wide-mouth glass tube. After 
mixing all the ingredients, the open end of the glass tube was covered 
with a lid to prevent loss of solvent from it and warmed in a water bath 
at 65 ± 3°C for ~5 min, until the surfactants were dissolved completely. 
Then, 1.6 ml of pH 7.4 phosphate buffer was added, and warming was 
continued on the water bath for ~2 min till a clear solution was observed. 
The mixture was allowed to cool down at room temperature until the 
dispersion was converted to a proniosomal gel [31,32].
Slurry method
carrier material to a 250-ml flask and the entire volume of surfactant 
solution was added the flask to form the slurry. If the surfactant solution 
volume is less, then additional organic solvent can get slurry. The flask 
was attached to a rotary evaporator was applied until the free-flowing. 
The flask was removed from the evaporator and kept under vacuum 
overnight. The proniosome powder was stored in sealed containers at 
4°C. The time required to produce proniosomes is independent of the 
ratio of surfactant solution to the carrier material and appears to be 
scalable [33-35].
Slow spray - coating method
This method involves preparation of proniosomes by spraying 
surfactant in an organic solvent onto carrier material and then 
evaporating the solvent. Since the carrier is soluble in the organic 
solvent, it repeats the process until the desired has been achieved. 
The surfactant coating on the carrier is very thin, and hydration of this 
coating allows multilamellar when the carrier dissolves [36,37]. The 
resulting noisome is very similar to those produced by conventional 
methods, and the size distribution is more uniform. It is suggested 




Proniosomal gel (0.2 g) was reconstituted with 10 ml of pH 7.4 
phosphate buffer in a glass tube. The aqueous suspension was 
sonicated in a sonicator bath for 30 min. The naproxen containing 
niosomes were separated from the untrapped drug by centrifuging at 
9000 rpm at 4°C for 45 min. The supernatant was taken, and the drug 
concentration in the resulting solution was assayed by ultraviolet (UV) 
spectrophotometer at a specific wavelength. The percentage of drug 
encapsulation was calculated by the following equation:
EE%=[(Ct–Cf)/Ct]×100.
Where Ct is the concentration of a total drug and Cf is the concentration 
of a free drug [15,39].
Vesicle size and zeta potential analysis
The mean vesicle size, size distribution, and zeta potential were 
determined using a Dynamic Light Scattering technique by Malvern-
Zetasizer (Nano ZS90). In a glass tube, 0.2 g proniosome gel was diluted 
with 10 ml of pH 7.4 phosphate buffer. The vesicle measurements were 
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done at a temperature of 25±0.5°C. The polydispersity index (PI) was 
determined as a measure of homogeneity. PI is obtained as:
PI=(SD/vesicle size).
Small values of PI (<0.1) indicate a homogeneous population, while PI 
values >0.3 indicate high heterogeneity [40].
MICROSCOPICAL EXAMINATION
Optical microscope
In a glass tube, 0.2 g proniosome gel was diluted with 10 ml of pH 7.4 
phosphate buffer; a few drops of the formed niosomal dispersion were 
spread on a glass slide and examined for the presence of insoluble drug 
crystals using an ordinary light microscope with varied magnification 
powers (×10 and ×40). Photomicrographs were taken using a digital 
camera [40].
Scanning electron microscopy (SEM)
The shape, surface characteristics, and size of the proniosomes were 
observed by SEM. In an attempt to illustrate the role of cholesterol in 
vesicle formation, the morphological differences in shape and surface 
characteristics of the prepared proniosome derived noisome of 
formulae having different cholesterol contents were examined using 
a scanning electron microscope. In a glass tube, 0.2 g proniosome gel 
was diluted with 10 ml of pH 7.4 phosphate buffer; the dispersion was 
sprinkled and fixed on an SEM holder with double-sided adhesive tape 




This method help to study the possible interactions between drug and 
vesicle ingredients by taking thermal properties. Thermal properties 
of the pure drug and the formulation were evaluated by differential 
scanning colorimetry (DSC) using a diamond (DSC) (Mettler star 
sw8.10). The analysis was performed at a rate 50c min-1 to 200oc 
temperature range under a nitrogen flow of 25 ml/min. Highest EE% 
was chosen, and samples of 4 mg of each drug, surfactants, empty and 
drug-loaded proniosomes-derived niosomes were submitted to DSC 
analysis. The weighed amount of sample was then held from room 
temperature to 300°C at a rate of 10°C/min [42].
Fourier transforms infrared spectroscopy (FTIR)
Drug powder was compressed into a pellet along with KBr using 
a hydraulic press. The IR spectrum of drug and final optimized 
formulations were recorded in the wavenumber region of 4000–
400 cmˉ1 on FTIR [42].
IN VITRO RELEASE
The release study employed the vertical glass Franz diffusion cells which 
have a diffusional surface area of 1.13 cm2 with the receptor compartment 
of 10 ml volume [43]. The cellulose dialysis membrane was soaked in 
distilled water overnight before cutting into suitable pieces. This soaking 
was conducted to ensure complete swelling of the membrane to provide 
a constant pore diameter throughout the experiment. The membrane 
was then mounted between the donor and receptor compartments 
before filling the receptor compartment with pH 7.4 phosphate buffer. 
The diffusion cells were incubated into a thermostatically controlled 
circulator water bath. The temperature of the receptor compartment was 
maintained at 37±0.5°C, and the receiver medium was continuously stirred 
to prevent any boundary layer effects. Weight amount of proniosomal gels 
were loaded into the donor compartments; then it was covered with an 
aluminum foil to prevent evaporation. At predetermined time intervals, 
namely 1, 2, 3, 4, 6, 8, 12, 18, and 24 h, samples of 1 ml were taken from the 
receptor compartment and replaced immediately by fresh buffer solution; 
to maintain the “sink” conditions constantly and a constant volume as 
well. The samples were then assayed spectrophotometrically. All release 
experiments were done in triplicates. The plot of cumulative percentage 
drug release was plotted against time. The obtained release data were 
subjected to kinetic treatment according to zero, first, Hixson Crowell, 
and Higuchi diffusion models. The correlation coefficient (r), the order of 
release pattern was determined in each case.
RATE OF SPONTANEITY (HYDRATION)
The spontaneity of niosome formation is described as the number 
of niosomes formed after hydration of proniosomes for 15 min [44]. 
Proniosomal gel (10 mg) was transferred to the bottom of a small-
stoppered glass tube and spread uniformly. 1 ml of pH 7.4 phosphate 
buffer was added along the walls of the test tube and kept aside without 
agitation. After 15 min a drop of hydrated sample was withdrawn and 
placed on Neubauer’s chamber for counting number of niosomes eluted 
from a proniosomal gel.
PHYSICAL STABILITY
Aggregation or fusion of the vesicles as a function of temperature was 
determined as the change in EE after storage [45]. The vesicles were 
stored in glass vials at room temperature (37°C) or kept in a refrigerator 
(4–8°C) for 3 months. The retention of entrapped drug and the mean 
particle size were measured after preparation and then after 1, 2, and 
3 months of storage in an optimized formulation. Further, at the end 
of each month, the samples were also observed for any sign of drug 
crystallization under an optical microscope. Stability for formulation 
was defined in terms of retaining its initial EE for 3 months duration. 
A stable formulation was defined as those showing high EE (>60%) and 
high drug retention value (>90%), at each time interval.
Drug retained in proniosomes=(Entrapped drug after storage/
entrapped drug before storage) ×100.
Concise evidence of published proniosomal gel formulations and 
its influence on pharmacology
Astudy by Xu et al. revealed tacrolimus (FK506) for its ophthalmic 
delivery with a potential approach of proniosome derived niosomes 
Fig. 1: Types of dry granular proniosomes




Alkyl ethers and 
alkyl glyceryl ethers
Polyoxyethylene 4 lauryl ether (Brij 30)
Polyoxyethylene cetyl ethers (Brij 52, 56, 58)
Polyoxyethylene stearyl ethers (Brij 72, 76)
Sorbitan fatty acid 
esters
Span 20, 40, 60, 80
Polyoxyethylene 
fatty acid esters
Tween 20, 40, 60, 80
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with enhanced corneal permeation for effective anti-allograft rejection 
and ocular irritation. Researchers successfully formulated proniosomes 
loaded with FK506, incorporated lecithin as a surfactant and poloxamer 
188, cholesterol acts as a stabilizer. With a small amount of ethanol 
and water in a trace amount, reconstituted to niosomes before to use. 
Prepared formulation was characterized for morphology, size, and zeta 
potential, and the surface tension was significantly lowered that enabled 
easy wettability of the hydrophobic surface of the corneal epithelium 
contributing for enhanced spreadability and enhanced permeation 
with high EE and also assessed for its stability. Furthermore, in vitro 
study on isolated rabbit corneal disclosed permeation of FK506 from 
niosomes significantly greater than that from control (Protopic®). 
Authors suggested that enhanced transcorneal permeation was due to 
poloxamer 188 and surfactant property of lecithin acted as penetration 
enhancers, surfactants improved solubility of FK506 significantly 
and low surface tension, enabled niosomes with desired wetting and 
spreading properties, and also drug retention studies in the cornea 
showed significantly high drug retention for the preparation than 
ointment. They postulated niosomes with the enhanced permeation 
of FK506 would achieve an effective therapeutic drug concentration 
for eye diseases through topical administration. Ocular irritation 
studies revealed no evidence of irritation when compared preparation 
and saline control group with no statistical difference. Histological 
investigations showed formulation influence on tissue integrity and 
corneal cell structure. The results demonstrated superior corneal 
biocompatibility of the prepared niosomes. In vivo studies were 
examined for immunosuppressive for topically administrated niosomes, 
in Wistar and Sprague-Dawley strains of rats. Results showed niosomes 
treated groups decreased corneal allograft rejection incident with 
significantly extended corneal allografts survival time when compared 
with control and blank groups. In conclusion, FK506 niosomes showed 
potential ophthalmic delivery [46].
Gagandeep Benipal formulated a novel proniosomal system with 
ketoconazole (KTZ) where non-ionic surfactant (span 60) constituted 
proniosomes and assured enhanced delivery of KTZ transdermally 
under occlusive conditions. The author performed various in vitro 
tests which included encapsulation efficiency, size, and shape; a further 
formulation was optimized based on in vitro release and stability 
studies. The formulation showcased high EE, and exhibited vesicle 
size recommended for efficient transdermal delivery. They had also 
described the major role of cholesterol and lecithin concentrations 
for EE of a prepared formulation. From in vitro release studies, the 
developed proniosomal formulation guided significant protracted 
release profile compared to a conventional carbopol formulation. 
Stability studies proposed optimum 5±3°C for storage of the prepared 
formulation and observed no alteration in EE for the test period of 
90 days. In conclusion, proniosomal gel loaded with KTZ exhibited 
potential delivery system [47].
In another study tazarotene, proniosomal gel was developed by 
Prasad and Chaurasia, where they developed the proniosomes 
employing coacervation phase separation composed of stearylamine, 
span, lecithin, and cholesterol for topical delivery [48]. Span 60 was 
determined to yield high efficiency for encapsulation. They postulated 
with high hydrophobicity along with little packing behavior and a 
minimal amount of cholesterol it yields optimum lamellarity. Authors 
determined morphological characteristics for proniosomes with gold-
palladium sputtered vesicles that were investigated with a scanning 
electron microscope which revealed well-distinguished vesicles with 
spherical and sharp boundaries on hydration. Further span 60 with 
higher HLB values showed smaller vesicles due to reduced surface 
free energy. Proniosomal gel showed promising in vitro release, 
and penetration, its release from the formulation was examined by 
employing pre-conditioned cellulose membrane, latter study was 
conducted using Franz diffusion cell, taking Wistar rat skin. Results 
concluded tazarotene release rate was appreciably higher than its flux 
against rat skin, rendering to barrier properties of skin. Hypothesis 
indicated drug permeation into the skin, with no significant systemic 
circulation, provided strong evidence of drug permeation into the skin, 
efficient for psoriatic therapy. Stability study showed no significant 
characteristic alterations with vesicular size and encapsulation 
efficiency of tazarotene for developed preparations at room temperature 
and refrigeration conditions. Histological examinations of transverse 
sections of rat tail indicated enhanced orthokeratosis associated with 
the formulation compared to the control group strengthening the 
effectiveness of the proniosomal therapy and its advantage for psoriasis 
treatment.
Miconazole antidermatophytic activity against Trichophyton rubrum 
was studied by Gupta et al. by loading the drug into proniosomal 
vesicles. Authors utilized coacervation-phase separation method 
for developing miconazole preparation by employing cholesterol, 
surfactants, and phosphatidylcholine [49]. Morphological and 
structural attributes were investigated using electron microscope 
yielded good results. They chose macro broth dilution technique 
for determining the minimum inhibitory concentration (MIC) of the 
preparation, for the study of pure cultures of Trichophyton rubrum, 
was considered. An activity of the vesicle gel in terms MIC was assessed 
against T. rubrumby taking different concentrations of preparation 
in DMSO, which was further incorporated in Sabouraud broth 
(T. rubruminoculated) in series of test tubes, results were concluded 
on the basis of turbidity. Furthermore, activity was determined using 
a disc diffusion method, discs impregnated with test formulation were 
placed on preconditioned media plates. Results revealed that with an 
increase in the concentration of miconazole distinct increase in the 
zone of inhibition. The drug release of vesicular gel determined to be 
remarkable when compared with control (non-vesicular preparation), 
and also the antifungal activity of vesicular preparation exhibited a 
prolonged release of medicament. Finally, the study indicated that 
developed formula had significant potential for topical delivery against 
dermatophyte and contributes in terms of efficacious drug delivery.
A recent study by Abdelbary et al. revealed the development of 
proniosomal gels loaded with KTZ for ocular delivery, where they 
prepared the gel employing coacervation phase method. Proniosomal 
gel was prepared by incorporating various nonionic surfactants 
and maintained a ratio 1:1 w/w with lecithin along with a fixed 
amount (50 mg) of cholesterol. Ultimately sufficient amount of water 
incorporated into the formulation to enable swelling of bilayer 
resulting in efficient vesicular structures [50]. Significantly highest 
EE was acquired for a formula with span 65 and lecithin in 1:1 w/w 
ratio. Authors postulated with an increase in alkyl chain number led 
to enhanced EE. Concerning proniosomal gel formulated using Brij 
surfactant, resulted in high EE with Brij 72 and 92, similarly when 
various grades of pluronics were utilized pluronic L121 showed higher 
EE. In vitro release studies showed biphasic release profiles for various 
formulae. An expeditious drug leakage was evident during the initial 
phase when incubated in a simulated lacrimal fluid, in subsequent 
phase a protracted release was observed. For Ex vivo, study corneas 
were isolated from albino rabbits, which were pre-conditioned with 
simulated lacrimal fluid. Permeability studies were achieved with 
Franz diffusion cell, where high flux was observed for proniosomes 
prepared with span 20, due to its lower transition temperature which 
enables the proniosomes to be in the fluid state which significantly 
affects the permeation. The researchers had significantly improved 
in vivo permeation, with about 20-fold increase in permeation across 
the corneal epithelium when compared to control. Furthermore, the 
test formula did not exhibit any sign of inflammation or alter tear 
production.
Sathyavathi et al. had formulated a niosomal system for ocular delivery 
loaded with brimonidine tartrate by thin-film hydration method with 
various ratios of span and cholesterol, where S-60 and cholesterol 
in the ratio of 2:1 showed high entrapment with extended release. 
Optimized formula further modified to in situ gelling system, using 
Carbopol 940 and HPMC to achieve localized action. The preparations 
showcased pseudoplastic rheology with protracted drug release. The 
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formula had shown significant lowered ocular pressure in male albino 
rabbits compared to marketed drops. Authors concluded that in situ 
niosomal system had potential applications compared to conventional 
therapy and enhanced ocular bioavailability [51].
Rita et al. prepared modified proniosomal gel of hydroxyzine 
hydrochloride with coacervation phase separation technique by 
screening with various non-ionic surfactants, along with phospholipids. 
Further the formula variables were optimized with taguchi statistical 
method. In vitro release study specified that formula with ratio 1:1 of 
surfactant:cholesterol showed prolonged release furthermore, the 
interaction of phospholipids with skin lipids retained drug molecule 
giving a sustained presence at the receptor site and achieve localized 
action. Similarly, ex vivo permeation study was performed with male 
Wistar rat’s skin, a formulation containing surfactant:cholesterol in the 
ratio of 1:1 significantly resulted in intact lipid layer and retard drug 
release and also enhanced the fluidity of the membrane. There was no 
sign of erythema and edema when tested on rabbit skin also optimized 
formula retained its stability for 3 months period and concluded 
refrigeration temperature optimum for storage with least leakage [52].
A transdermal proniosomal gel for Ketorolac was finished by Farooqui 
et al. from enhanced proniosomal suspension. Ketorolac by transdermal 
conveyance issues may emerge this can be limited by exemplification 
it with the new medication transporter. The proniosomes were set up 
by handshaking technique by dissolving cholesterol and surfactant in 
liquor; drug was broken up in phosphate cushion saline (PBS) pH 7.4. 
The PN suspension was kept refrigerated at 4°C. Carbopol 940 was 
utilized as a gelling specialist, and dimethylsulfoxide was utilized as 
entrance improving operator. The consolidation of proniosomal vesicles 
into the gel base decreased the in vitro medicates discharge from 
94.05%. The rate restraint of carrageenan-initiated paw edema 5 h in 
the wake of applying the positive control was observed to be 60.00%; 
the LCI-1-a gel was observed to be 63.44% while LCI-1-b and LCE-d gel 
indicated 57.44% and 49.08%. The LCI-1-a demonstrated promising 
skin saturation potential, better solidness, and higher ensnarement 
proficiency than LCI-1-b and LCB-1-g detailing. LCI-1-a demonstrated 
high medication discharge (94.048%) more than 17 h after topical 
use of upgraded PN plan when contrasted with LCI-1-b, LCB-1-g, and 
marketed formulation which recommends that PN definition (LCI-1-an) 
is far way better method of organization of KT through the fundamental 
dissemination [53].
An examination proposed by Litha Thomas, Vidya Viswanad was to 
create and factually streamline the proniosomal gel for upgraded 
transdermal conveyance utilizing 32 factorial plans to research the 
impact of both non-ionic surfactant and cholesterol to expand the 
entanglement effectiveness and transition Proniosomes were set 
up by a coacervation method. The last extent of surfactant alcohol 
aqueous stage was 54 w/w/w. The investigation demonstrated that 
the ensnarement proficiency relies on both cholesterol and surfactant 
while invasion progress depends just on the surfactant proniosomal gel 
demonstrated a fundamentally upgraded tranquilize pervasion through 
the skin, with an improvement proportion 3.81±1.85 at the point when 
stood out from the pharmaceutical game plan. The surfactant is an 
imperative part of the arrangement of niosomal vesicles and the variety 
in the focus may influence the entanglement effectiveness. The further 
augmentation in the center from 180 mg to 270 mg reduced the snare 
capability. The centralization of cholesterol is an essential part of the 
ensnarement of medication in the vesicles. The watched ensnarement 
proficiency was expanded fundamentally when cholesterol sum was 
expanded from 15 mg to 30 mg, however, additionally increment in the 
cholesterol diminished the entanglement effectiveness.
Proniosomal gel demonstrated an essentially improved medication 
penetrating through the skin, with an upgrade proportion 3.81±1.85 
precisely when showed up differently in association with the plan 
outline. Relative evaluation of immersion considers release in vitro 
examination of redesigned proniosomal gel (F5) with that of displayed 
gel and carbopol gel showed that the passageway of the enhanced 
specifying was updated 1.75 times in examination with that of the 
showed definition and the discharge was controlled. The change 
contemplates clearly exhibited that catch profitability depends both 
on the centralization of surfactant and cholesterol and drenching 
development relies on the gathering of surfactant so to speak, the 
examination shows that the definition upgrades the skin infiltration of 
prescription and the pushed separating did not display any plan issues 
related with it. The gel additionally passes the fleeting dependability 
ponders, demonstrating the physical and synthetic strength of the 
item. Consequently, the proniosomal gel is a proficient bearer for the 
conveyance of clotrimazole, in this manner delaying the activity [54].
An examination proposed by Radha and Chowdary. In conclusion, 
we can coat that proniosome ornidazole setup goes about as a store 
structure and shows reliable pharmaceutical release out of all 
recognizing made investigate 20 without lecithin demonstrates a most 
crucial measure of the portrayal of game plan inquired about quickly 
of each elective definition. Ornidazole proniosomal was set up by a 
coacervation-coordinate division system. When warming each and 
every one of the fixings was mixed well with a glass bar, the open side of 
the glass bottle was moored with a cover to store the loss of dissolvable 
from it and warm finished water shower at 60–70°C for around 5 min 
till the arranged authority blend was isolated completely. By then the 
fluid procedure (0.1% glycerol approach) was consolidated and warm 
a water shower until the moment that the minute that a sensible 
outline was incorporated that was changed over into proniosomal gel 
on cooling. The gel as requirements be tied down was anchored inside 
a relative glass bottle in decrease conditions for layout. A blended 
detailing of traverse 20 and traverse 40 reportable minimum sums 
sedate embodiment, though in skin penetration contemplates span 
20 indicated the high amount of medication pervasion looked at 
immediately of advertised ornidazole plan. FTIR examines were 
conveyed and demonstrated that there was no communication 
amongst API and utilized excipients SEM investigation of streamlined 
traverse 20 detailing showed that the span of the particles region unit 
in	differing	from	3	μm	to	30	μm	in	the	measure.	The	discharge	thinks	
about for detailing arranged from traverse 20 without lecithin indicated 
most noteworthy sum sedate arrival of 88% and traverse 20 definitions 
demonstrated 84% of medication discharge for 24 h. Incomparable 
way traverse 40 and traverse 60 additionally appeared around 70% 
of medication discharge, while advertised ornidazole fluid base gel 
demonstrated just 58% of medication discharge for 24 long stretches 
of study. The result of this examination demonstrates that proniosomal 
ornidazole gel plan is utilized for treating bacterial diseases locally and 
methodically for a higher medicinal guide [55].
Chandel et al. passed on preparation and assessment of proniosomal gel 
of neem seed oil using thin layer evaporation method for therapeutic 
purpose. It is gathered that it is down to earth to set up a satisfactory 
pronisomal gel of neem seed oil for helpful applications in which 
used materials are cholesterol, span 40, 60, 80, potassium dihydrogen 
phosphate and toluene, soya lecithin, sodium hydroxide and sodium 
chloride, and neem seed oil. The proniosomal gel was readied using 
cross 40, soya lecithin and cholesterol, using neem seed oil as the 
dynamic pharmaceutical settling. Alcohol and phosphate buffer pH 7.4 
were used in the formulation as pharmaceutical excipients. The ensuing 
subtle elements were evaluated by observing under transmission 
electron microscopy. Assessment of vesicle measurement and the 
molecule estimate run was finished utilizing the optical magnifying 
instrument. Appraisal of formulation yielded appropriate results like 
uniform size scattering 75–80% pharmaceutical entrapment and 
microbiological data. The antibacterial activities of formulations were 
evaluated by agar well diffusion method. For deciding the percent drug 
entrapment of proniosomal gel, 25 mg of neem seed oil was hydrated in 
80°C distilled water and vortexed for 2 min. The niosome scattering so 
acquired was centrifuged at 18000 rpm for 40 min at 5°C (Remi CPR-
24 rotator). The clear portion was utilized for the assurance of free 
medication at 310 nm spectrophotometrically [56].
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Das and Kumar made a study to deliver curcumin nano niosomes 
on skin to treat skin cancer by downregulation of cell proliferative 
controls involving thymine dimer, apoptosis, transcription factors 
NF-κB	and	of	inflammatory	responses	involving	COX-2,	PGE2,	and	NO	
and upregulation of p53 and p21/Cip1 which were prepared by reverse 
phase evaporation and materials used are Tween 65, Tween 60, and 
glyceryl monostearate as surfactant. Polymers such as carbopolhpmc 
and the combination of both were used for preparing the gel formulation 
in which nano niosomes were incorporated. After which gels tested for 
the spreadability, occlusion, and pH. The drug permeation study was 
conducted on treated Swiss albino mice abdominal skin and evaluated 
for anticancer effect. The chemoprophylaxis potential of curcumin 
was estimated by measuring the tumor burden, tumor volume, tumor 
incidence, and body weight. Average curcumin particle size was found 
between 0.0919 um and 1.9961 um measured by Brook Haven 90 Plus 
particle size analyzer and has its low solubility and physicochemical 
stability, rapid systemic clearance, and low cellular uptake. In vitro 
drug release from segregated nanovesicles was completed by dialysis 
technique in aqueous PEG400 (half v/v) at 37±1°C assessed by UV 
spectrophotometer at a wavelength of 437.50 nm [57].
An examination work performed by Preeti et al. The proniosomal 
gel of terbinafine hydrochloride was finished by coacervation stage 
detachment strategy. 100mg of medication alongside settled measures 
of soy lecithin and ethanol was blended with changed measures of 
excipient like traverse 40; cholesterol was utilized to get ready and 
assess the viability of proniosomes. The FTIR contemplates uncovered 
that there was no noteworthy cooperation of medication with the 
excipients. The in vitro thinks about uncover that the detailing containing 
high convergence of soy lecithin and cholesterol had high discharge 
when contrasted with different plans. The percent entanglement 
proficiency of all these nine clusters of the arranged proniosomal gel 
was observed to be 65.11–90.54. The optimized formulation contains 
Terbinafine hydrochloride (100 mg), span 40 (1350 mg), soy lecithin 
(900 mg), and cholesterol (250 mg) showed the highest percentage EE 
(90.54%) and slowest drug release in 24 h (66.6%) which indicate the 
prolonged drug release pattern of formulated proniosomal gel and is 
also stable for 1 month of period and forms spherical shape niosomes 
vesicles on hydration [58].
An examination on Proniosomal Gel for Boswellic Acids was performed 
by Mehta and Meenu, topical definition through the skin requires a 
non-dangerous, dermatologically adequate bearer, which not just 
control the arrival of the specialist for draw out activity yet, in addition, 
improves the infiltration to the skin layer. Boswellic acids have low oral 
bioavailability due to their lipophilic nature and not solubilizes into 
the intestinal liquid which restrains its foundational accessibility. High 
first-pass digestion likewise assumes an essential part in constraining 
the fundamental accessibility of BAs. Topical details upgrade the 
conveyance of lipophilic medications and sidestep the principal pass 
digestion which increments the fundamental accessibility of these 
medications. Proniosomal gel transporter framework can capture 
both hydrophilic and also hydrophobic specialists. Boswellic acids can 
join in the proniosomal gel conveyance framework. By consolidating 
the emulsifying activity of phospholipids with BAs, the medication 
and lipid complex gives upgraded bioavailability and enhanced 
pharmacokinetics. Proniosomal gel in the boswellic corrosive plan 
will prompt better focusing of medication at tissue goal give provoke 
beginning and delayed term of activity due to support of viable fixations 
in the skin in this way boswellic acids bioavailability issues can be 
survived [59].
An examination on proniosomal gel-interceded transdermal conveyance 
of bromocriptine (BCT) was performed by Lather et al. To explore the 
capability of a novel class of vesicular framework “proniosome” as a 
transporter for a transdermal conveyance of BCT. Proniosome plans 
were set up by the coacervation phase division technique. In which the 
proniosomes were set up by coacervation-stage detachment strategy. 
The 5 mg of BCT mix with soya lecithin and cholesterol were blended 
with ethanol blend and warmed on a water shower at 60–70°C until the 
point when it broke up. To this blend, phosphate cradle (pH 7.4) was 
included and warmed a water shower and permitted to cool at room 
temperature. Diverse evaluations of tweens and ranges were assessed 
for tranquilizing capture, and last vesicles estimate, percentage EE of 
the proniosomes was observed to be higher with ranges than with 
tweens. 90 mg of traverse 60 was picked as the improved sum for 
the arrangement of proniosomes. An expansion in surfactant fixation 
after a fitting level encourage the development of the blended micelles 
which can follow alongside the niosomal vesicles, accordingly indicate 
expanded size and brought down medication epitome. Proniosomes 
showed a maintained discharge example of BCT in vitro. Skin saturation 
examines uncovered high entrance of proniosomes with the supported 
arrival of BCT through rodent skin. The upgraded proniosomal definition 
demonstrated the improved transdermal motion of 16.15 mg/cm2/h 
when contrasted with 3.67 mg/cm2/h for tranquilize scattering. The 
created details were seen as non-aggravation to the rodent skin and 
were found as very steady at 4 and 25°C for 90 days w.r.t. vesicle size 
and medication content. The dried proniosomal plan could go about as 
a promising other option to niosomes and ideally for the transdermal 
conveyance of BCT. Dry proniosomal gel showed the arrangement of 
1.3 mm measured smooth circular pernicious vesicles after hydration. 
Traverse 60 was observed to be the most suitable surfactant for the 
arrangement of proniosomes. Lecithin, cholesterol, and medication 
were additionally examined and enhanced. Proniosomes displayed 
98.9% of ensnarement productivity and encouraged a managed 
arrival of embodied medication. The proniosomal detailing enhanced 
the transdermal transition of medication scattering by 4.4 times 
when assessed utilizing ex vivo skin pervasion consider. The created 
definition was observed to be non-aggravation to the rodent skin. 
The high dependability supports the capability of proniosomes for a 
fundamental conveyance of therapeutics [60].
Acharya and Kumar formulated candesartan cilexetel proniosomal 
gel shows increased bioavailability with a novel approach and carried 
out in vitro - in vivo evaluation studies to the developed formulation. 
Candesartan cilexetel gel was developed by the slurry method using 
non-ionic surfactants such as span 60, tween 60, and maltodextrin 
as a carrier followed by cholesterol, and soya lecithin as a stabilizer 
for preparation of proniosomal gel. Authors prepared dry powder of 
candesartan proniosomes by taking different concentrations of drug, 
carrier ratio, dissolved in 2:1 ratio. Methanol, chloroform was added and 
sonicated for 10 min, adding maltodextrin in the required amount. All 
the materials were fill in RB flask attached to a rotary flask evaporator 
to evaporate solvent 60–70 rpm until dry, free-flowing product obtained. 
Then, resulted from proniosomes hydrated with ph 6.8 phosphate buffer 
at 80°C add 1% w/v carbopol 934 to the niosomal suspension to niosomal 
gel. The gel was evaluated for the drug content analysis, vesicle size PH 
determination, viscosity and rheological studies. In vivo BA studies, 
conducted by albino rats, blood samples were withdrawn from the tail 
vein of rats and obtained the pharmacokinetic parameters Cmax, Tmax, and 
AUC-t. The concentration levels maintained throughout 24 h, increased 
relative BA more than the oral route with high of Tmax 6 h, whereas 4 h for 
the oral route. Hence, the proniosomal gel provides longer plasma drug 
concentration time than the oral route. It is better for the treatment of 
the hypertension patients. In vitro skin permeation studies carried out 
for proniosomal gel candesartan using rat skin. It showed higher drug 
permeation with span 60 than tween 60 due to the larger size of vesicles, 
less lipophilic nature, and lower skin permeation which make difficulty 
to penetrate through the skin of tween 60 containing formulation. 
Better skin permeation, flux, permeability coefficient, enhancement 
ratio showed formulation 2:1 ratio of span 60, cholesterol. The in vitro 
release studies profile found to be with biphasic results first 6 h rapid 
release followed by controlled release up to 24 h proniosomal vesicles 
are smaller in size, with spherical in shape, uniform surface confirmed 
SEM analysis and there is no aggregation, agglomeration found in a 
niosomal gel. Better EE with span 60, i.e., 86.7%, 62.7% with twee 60 
found ph of gel found in the range of 6.7–7.3. Hence, it is a comfort to the 
physiological acceptance for the topical application. The FTIR spectrum 
60
Asian J Pharm Clin Res, Vol 12, Issue 1, 2019, 54-61
 Rajkumar et al. 
confirmed there is no significant change in the chemical integrity of drug 
and polymers. Optimized formulations were studied for stability studies 
as per the ICH guidelines, the observed effect of temperature, humidity 
effect on the gel founded within acceptable limits. Hence, finally the 
prepared formulation of candesartan proniosomal gel concluded as 
stable increased BA than the oral dose, delivery of a drug in a sustained 
manner for an extended period of time, so the formulation is the better 
option in the treatment of hypertension with better patient compliance 
and comfort [61].
Another study by Badawi et al., developed dispersed permethrin 
proniosomesin powder and microemulsion based hydrogel for the 
treatment of scabies, the powdered proniosomes showed good flow, 
cyclohexane used as a solvent in preparation, it is less volatile than 
acetone also added cholesterol, Brij in formulation resulting highest 
entrapment. Topical proniosome prepared by modified slurry method 
without vacuum, Aerosil 200 used as insoluble carrier resulted into 
white color good flow granular powder. Tapped density found to 
be 0.498 g/ml, cars index 0.408 g/ml and assay of permethrin was 
98.2%, and permeation retention of proniosomes was 55.6%. However, 
unstable at accelerated stability storage conditions. Hence, a base adds 
to it for topical application for patient convenience and to overcome 
stability problems. Microemulsion-based hydrogel permethrin 5% 
was prepared it was a clear light yellow indicates no crystals present 
in it. Moreover, it is transparent yellow color shows homogeneity at 
97.5%. Stable physically, after 6 months finally authors conclude that 
proniosomes of the permethrin microemulsion based hydrogel is 
more effective than powder form and stable one and showed better 
spreadability, adhesion, viscosity, extrusion, and hydration finally 
comfort to apply to the patient for the treatment of scabies [62].
Fouda et al. had developed dorzolamide sustained ocular delivery of 
proniosomal formulation. Coaservation phase separation method was 
used for the preparation of formulation by utilizing 52 full factorial 
design method. They studied the effect of surfactants (span40) and 
cholesterol amounts variations (independent variables) on the %EE, 
the particle size of prepared formulations. Results showed that the 
1:9 ratios of cholesterol and span 40 significantly affect the %EE. 
The optimized formulation was selected and carried out intraocular 
pharmacodynamics study on rabbits, and it was found in the higher 
reduction in intraocular pressure than the marketed eye drops, 
i.e., Trusopt. Hence, the final conclusion of this study is dorzolamide 
proniosomal gel increased the bioavailability and successfully sustained 
the reduction of intraocular pressure. Dorzolamide proniosomal gel 
is a very promising drug delivery system used for the treatment of 
glaucoma disease [63].
CONCLUSION AND FUTURE PROSPECT
Proniosomal gel contains different kinds of constituents and selection 
of components need necessitate knowledge because properties of 
components changing from each other. Which includes surfactant, 
lecithin, cholesterol, and the role of method of manufacturing have 
specific advantages which induce quality of final formulation. Thus, the 
development of stable proniosomal gel purely depending on the suitable 
ingredients and methodology involved the proniosomal gel preparation 
is a better comfort, stable and extensively used in drug targeting for 
controlled release of both hydrophilic and hydrophobic drugs. The 
gel property of proniosomes maintaining better skin penetration and 
physicochemical properties. Whereas cholesterol gives stability and 
permeability to the vesicles by overcomes of, for example, aggregation, 
fusion, drug leakage, or hydrolysis of the active compounds; therefore, 
proniosomal gel formulations novel transdermal dosage form is open 
for research to target specific dermatological as well as other systemic 
skin disorders. Topical administration of proniosomal gel for the 
treatment of melanoma, psoriasis, bacterial, and fungal infections can 
be anticipated successfully by the development of proniosomal gel 
formulation. More researches are carried out in this field to know the 
exact potential of this novel drug delivery system.
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